The all-new "US Politics and coronavirus" thread pt. 3
View Single Post
11th December 2020, 05:30 PM
Join Date: Feb 2005
According to the Regeneron webpage: Re 3rd phase clinical trials
CASIRIVIMAB AND IMDEVIMAB
SARS-CoV-2 Virus Multi-Antibody Therapy Treatment for certain hospitalized and non-hospitalized patients with COVID-19; prevention of COVID-19 in household contacts of diagnosed patients
Company news releases REGENERON’S CASIRIVIMAB AND IMDEVIMAB ANTIBODY COCKTAIL FOR COVID-19 IS FIRST COMBINATION THERAPY TO RECEIVE FDA EMERGENCY USE AUTHORIZATION
Authorized for recently diagnosed, mild to moderate COVID-19 in high-risk patients
Initial doses will be made available to approximately 300,000 patients, with no medication out-of-pocket costs, under U.S. government allocation program ...
The clinical evidence from Regeneron’s outpatient trial suggests that monoclonal antibodies such as casirivimab and imdevimab
have the greatest benefit when given early after diagnosis and in patients who have not yet mounted their own immune response or who have high viral load.
View Public Profile
Find More Posts by Skeptic Ginger